707 related articles for article (PubMed ID: 10711745)
1. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
Toth K; Kesmarky G; Vekasi J; Nemes J; Czopf L; Kapronczay P; Halmosi R; Papp E; Juricskay I
Clin Hemorheol Microcirc; 1999; 21(3-4):209-16. PubMed ID: 10711745
[TBL] [Abstract][Full Text] [Related]
2. Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension.
Toth K; Nemes J; Czopf L; Kapronczay P; Kesmarky G; Juricskay I
Clin Hemorheol Microcirc; 1999; 20(1):57-61. PubMed ID: 11185685
[TBL] [Abstract][Full Text] [Related]
3. [Hemorheologic factors in hypertensive and diabetic retinopathy].
Vékási J; Márton Z; Késmárky G; Cser A; Russai R; Kovács B
Orv Hetil; 2001 May; 142(20):1045-8. PubMed ID: 11407065
[TBL] [Abstract][Full Text] [Related]
4. Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension.
Tsuda Y; Satoh K; Kitadai M; Izumi Y; Takahashi T
Arzneimittelforschung; 1997 Aug; 47(8):900-4. PubMed ID: 9296274
[TBL] [Abstract][Full Text] [Related]
5. Effects of antihypertensive therapy on hemorheological profiles in female hypertensive patients with initially low or high whole blood viscosity.
Muravyov AV; Meiselman HJ; Yakusevich VV; Zamishlayev AV
Clin Hemorheol Microcirc; 2002; 26(2):125-35. PubMed ID: 12082261
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
7. Hemorheological alterations in patients with diabetic retinopathy.
Vekasi J; Marton ZS; Kesmarky G; Cser A; Russai R; Horvath B
Clin Hemorheol Microcirc; 2001; 24(1):59-64. PubMed ID: 11345235
[TBL] [Abstract][Full Text] [Related]
8. [Effects of cardiovascular risk factors on hemorheologic parameters in cerebrovascular patients].
Szapáry L; Szóts M; Horváth B; Márton Z; Alexy T; Késmárky G; Juricskay I; Nagy F; Gaál V; Pálfi A; Koltai K; Tóth K
Orv Hetil; 2003 Jun; 144(22):1085-90. PubMed ID: 12847818
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in hemorheological parameters of coronary artery disease patients.
Bogar L; Juricskay I; Kesmarky G; Feher G; Kenyeres P; Toth K
Clin Hemorheol Microcirc; 2006; 35(1-2):99-103. PubMed ID: 16899912
[TBL] [Abstract][Full Text] [Related]
10. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy.
Vekasi J; Koltai K; Gaal V; Toth A; Juricskay I; Kesmarky G
Clin Hemorheol Microcirc; 2008; 39(1-4):385-9. PubMed ID: 18503149
[TBL] [Abstract][Full Text] [Related]
11. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha.
Furuland H; Linde T; Sandhagen B; Andrén B; Wikström B; Danielson BG
Scand J Urol Nephrol; 2005; 39(5):399-404. PubMed ID: 16257842
[TBL] [Abstract][Full Text] [Related]
12. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases.
Feher G; Koltai K; Kesmarky G; Horvath B; Toth K; Komoly S; Szapary L
Phytomedicine; 2009 Mar; 16(2-3):111-7. PubMed ID: 19135345
[TBL] [Abstract][Full Text] [Related]
13. Hemorheological parameters in coronary artery disease.
Kesmarky G; Toth K; Habon L; Vajda G; Juricskay I
Clin Hemorheol Microcirc; 1998 Jul; 18(4):245-51. PubMed ID: 9741664
[TBL] [Abstract][Full Text] [Related]
14. Hemorheological background of acetylsalicylic acid resistance.
Feher G; Koltai K; Kesmarky G; Toth K
Clin Hemorheol Microcirc; 2008; 38(3):143-52. PubMed ID: 18239256
[TBL] [Abstract][Full Text] [Related]
15. [Hemorheological alterations in hypertensive patients].
Foresto P; D'Arrigo M; Filippini F; Gallo R; Barberena L; Racca L; Valverde J; Rasia RJ
Medicina (B Aires); 2005; 65(2):121-5. PubMed ID: 16075805
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
17. The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction.
Toth K; Bogar L; Juricskay I; Keltai M; Yusuf S; Haywood LJ; Meiselman HJ
Clin Hemorheol Microcirc; 1997; 17(2):117-25. PubMed ID: 9255435
[TBL] [Abstract][Full Text] [Related]
18. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Chapman N; Chang CL; Dahlöf B; Sever PS; Wedel H; Poulter NR;
Circulation; 2008 Jul; 118(1):42-8. PubMed ID: 18559700
[TBL] [Abstract][Full Text] [Related]
19. The effect of simvastatin therapy on hemorheological profile in coronary heart desease (CHD) patients.
Muravyov AV; Yakusevich VV; Surovaya L; Petrochenko A
Clin Hemorheol Microcirc; 2004; 31(4):251-6. PubMed ID: 15567894
[TBL] [Abstract][Full Text] [Related]
20. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
